About Us Careers Contact Us

Home
Products
Isotope Labeled Active Pharmaceutical Ingredients (APIs)
Baloxavir-[d4]

Inquiry List

* Name:
* Phone:
* Service & Products of Interested: [Isotope Labeled Active Pharmaceutical Ingredients (APIs)] Baloxavir-[d4] (BLP-003387)
Project Description:
* Quantity
* Email:
* Organization We recommend you to leave us your work email address so that we can serve you better. Please leave your organization information here if you don't have a work email address.
* Verification Code:

Our Highlights

Optimal Prices
Buying products on this site guarantees the best price
Flexible Batches
Flexible batch size to meet different needs of global customers
Prompt Delivery
Warehouses in multiple cities to ensure timely delivery
Quality Assurance
Strict process parameter control to ensure product quality
One-to-one Customization
One-to-one custom synthesis for special structural needs

Application Area

Environmental

Stable isotope-labeled compounds are used as environmental pollutant standards for the detection of air, water, soil, sediment and food.

Clinical diagnostic

In addition to treating various diseases, isotopes are used for imaging, diagnosis, and newborn screening.

Organic Chemistry

Small molecule compounds labeled with stable isotopes can be used as chemical reference for chemical identification, qualitative, quantitative, detection, etc. Various types of NMR solvents can be used to study the structure, reaction mechanism and reaction kinetics of compounds.

Metabolic Research

Stable isotope labeling allows researchers to study metabolic pathways in vivo in a safe manner.

Baloxavir-[d4]

Inquiry

General Information
Catalog: BLP-003387
CAS: 2415027-80-2
Molecular Formula: C24H15D4F2N3O4S
Molecular Weight: 487.51

Chemical Structure

Ordering Information

Catalog Number	Size	Price	Stock	Quantity
BLP-003387	2 mg	$1099	In stock

Add to cart

Description

Baloxavir-[d4] is an isotope compound of Baloxavir. Baloxavir marboxil is a first-in-class, one-dose oral medicine with a novel proposed mechanism of action that has demonstrated efficacy in a wide range of influenza viruses, including in vitro activity against oseltamivir-resistant strains and avian strains (H7N9, H5N1) in non-clinical studies. Baloxavir is a polymerase acidic, cap-dependent, endonuclease inhibitor that is indicated for the treatment of acute uncomplicated influenza in patients aged 12 years and older who have been symptomatic for no more than 48 hours. It blocks viral proliferation by binding to one of two endonuclease binding sites, inhibiting the initiation of mRNA synthesis for both influenza A and influenza B strains. Baloxavir can interact with polyvalent cation-containing products, which can decrease its plasma concentration.

Related CAS

1985605-59-1 (unlabelled)